A groundbreaking study published on July 30, 2025, explores the rejuvenation of skeletal muscle in mice through senomorphic treatment using the antiviral drug maraviroc. This research highlights the significance of dose, timing, and duration of treatment on muscle regeneration.

Introduction

Muscle senescence is a major contributor to the deterioration of muscle function with age, often leading to a condition known as sarcopenia. The researchers set out to create a genetic atlas of senescent cells in muscle tissue, thereby improving understanding of this phenomenon. In their findings, they reveal that maraviroc shows a potential therapeutic benefit in combating senescence-related muscle weakness.

Aging Muscle Tissue

One of the primary characteristics of aging muscle tissue is the presence of the senescence-associated secretory phenotype (SASP), which comprises numerous pro-inflammatory compounds. This SASP is implicated in muscle function decline. Prior studies have yielded conflicting results regarding the effect of senescence on muscle function. On one side, drugs like dasatinib and quercetin, known as senolytics, have been shown to enhance muscle strength in aged models [2]. Conversely, other research has illustrated how pro-senescent therapy may facilitate muscle regeneration [3].

Research Methodology

The study collected biopsies from hamstring muscles of ten male donors, comprising five young individuals aged 19-27 years and five aged individuals between 60-77 years. The researchers extracted gene activity information from mononucleated cells specifically prone to senescence. Analysis of epigenetic markers and gene expressions resulted in a segmentation of muscle-resident cells into twelve distinct clusters. Notably, aged cells exhibited a reduced population of muscle stem cells.

Senescence Dynamics in Muscles

The study identified heightened prevalence of senescent cells within aged muscle across four distinct cell types. SASP dynamics analysis revealed a subset of factors with shared expression among these cells, though remarkably, over 30% showcased cell-type specificity. Significantly, the CCR5 receptor and various chemokines (CCL3, CCL4, CCL5) linked to this receptor were markedly elevated in aged muscle stem cells.

Rejuvenating Muscles with Maraviroc

The researchers tested maraviroc through a high-dose short-term treatment regimen, which significantly rejuvenated muscle tissue in 18-month-old mice. Key findings included:

  • Increased Muscle Mass and Fiber Size: Enhanced regenerative capabilities were noted with maraviroc treatment.
  • Reduced Inflammation: Inflammatory markers decreased in treated specimens.
  • Improved Muscle Function: Enhanced grip strength and increased running speed and distance were observed.

Furthermore, at the molecular level, the therapy was associated with increased muscle stem cells and a marked decrease in pro-inflammatory macrophages. Notably, the impact of maraviroc was age-specific, with null or adverse effects noted in younger mice.

Understanding the Regulation of Senescence and SASP

Research efforts also aimed to identify the transcription factors that govern senescence and SASP induction. The team focused on transcription factors including NF-κB1 and C/EBPB, plus the lesser-known AP-1 family members, specifically ATF3 and JUNB. Key findings included:

  • ATF3's Role: It was found to regulate several genes associated with senescence.
  • JUNB’s Function: Although it did not directly affect senescence marker expression, JUNB emerged as an important regulator of SASP production.

Potential Therapeutic Candidates and Future Directions

The authors assert that the construction of the first atlas of senescence in human skeletal muscle lays the groundwork for advancing the understanding of the variances in senescence. While maraviroc appears promising, its efficacy in human subjects remains to be established. Future research aims to:

  • Conduct focused screenings for other senolytic or senomorphic compounds.
  • Expand upon the findings regarding the unique features of senescent cells within skeletal muscles for targeted therapeutic interventions.

In conclusion, while this study highlights the remarkable potential of maraviroc in addressing muscle senescence, it emphasizes the importance of further explorations to enhance treatment strategies for conditions like sarcopenia.

Literature

“Creating an atlas of senescence in human skeletal muscle provides vital insights into its complexity and assists in innovating therapeutic designs.” – Research Team

[1] Li, Y., et al. (2025). Multiomics and cellular senescence profiling of aging human skeletal muscle uncovers Maraviroc as a senotherapeutic approach for sarcopenia. Nature communications, 16(1), 6207.

[2] Xu, M., et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nature medicine, 24(8), 1246–1256.

[3] Saito, Y., & Chikenji, T. S. (2021). Diverse Roles of Cellular Senescence in Skeletal Muscle Inflammation, Regeneration, and Therapeutics. Frontiers in pharmacology, 12, 739510.

[4] Li, Y., et al. (2025). Skeletal muscle stem cells modulate niche function in Duchenne muscular dystrophy mouse through YY1-CCL5 axis. Nature communications, 16(1), 1324.

Note: This article is part of the Lifespan Research Institute's commitment to providing open-access research and insights into the aging and regenerative medicine fields. Contributions from readers allow us to maintain our independent journalism.